In Vivo Pharma Intelligence | The Growth Path for Drug Discovery Partners
Nov 2022
Originally published by In Vivo Pharma Intelligence on November 15, 2022
James West, Director in Lincoln’s Healthcare Group, explains the key trends and mergers and acquisitions (M&A) dynamics in the drug discovery industry.
Summary
-
James West, Director in Lincoln’s Healthcare Group, shares with In Vivo Pharma Intelligence the key trends and M&A dynamics in the drug discovery industry.
- Sign up to receive Lincoln's perspectives
Contributor
Related Perspectives
PETS International | Consolidation Meets Regulation in the Veterinary Clinics Market
Originally posted by PETS International on April 5, 2024. Animal health is becoming a big business in Europe and the U.S. Thus, regulators are turning a closer eye to mergers… Read More
“Leader to Leader” Series
The Leader to Leader video series turns up the dial on rich conversations with prominent leaders – from business owners and entrepreneurs to investors and CEOs – highlighting their stories… Read More
What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access
The cost of developing new drugs is staggering. Among the top 20 global biopharmas, the average cost of developing a candidate from discovery through clinical trials to market was approximately… Read More
Investment Opportunities in Pharma: A Data-Driven Exploration of CDMO Appeal
The report discusses the current state of the contract development and manufacturing organization (CDMO) market within the pharmaceutical industry, emphasizing the increased interest from private equity (PE) investors. The pharmaceutical… Read More
